Iael Weissberg Minutentag

Dr. Iael Weissberg Minutentag

Sao Paulo State University (Unesp), São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
VSVanessa G. P. Souza
Vanessa G. P. Souza
RARachel Paes de Araújo
Rachel Paes de Araújo
MSMariana R. Santesso
Mariana R. Santesso
ASAna Laura Seneda
Ana Laura Seneda
Iael Weissberg MinutentagIael Weissberg Minutentag
Iael Weissberg Minutentag
PRPatricia Reis
Patricia Reis
Lung cancer is one of the most frequent tumors that metastasize to the brain. Brain metastasis (BM) is common in advanced cases, being the major cause of patient morbidity and mortality. BMs are thought to arise via the seeding of circulating tumor cells into the brain microvasculature. In brain tissue, the interaction with immune cells promotes a microenvironment favorable to the growth of cancer cells. Despite multimodal treatments and advances in systemic therapies, lung cancer patients still have poor prognoses. Therefore, there is an urgent need to identify the molecular drivers of BM and clinically applicable biomarkers in order to improve disease outcomes and patient survival. The goal of this review is to summarize the current state of knowledge on the mechanisms of the metastatic spread of lung cancer to the brain and how the metastatic spread is influenced by the brain microenvironment, and to elucidate the molecular determinants of brain metastasis regarding the role of genomic and transcriptomic changes, including coding and non-coding RNAs. We also present an overview of the current therapeutics and novel treatment strategies for patients diagnosed with BM from NSCLC.

Verified
Journal Article
Open access
PDF file
VSVanessa G. P. Souza
Vanessa G. P. Souza
AFAisling Forder
Aisling Forder
LBLiam Jerome Brockley
Liam Jerome Brockley
MPMichelle E. Pewarchuk
Michelle E. Pewarchuk
NTNikita Telkar
Nikita Telkar
PRPatricia Reis
Patricia Reis
Liquid biopsies have emerged as a promising tool for the detection of metastases as well as local and regional recurrence in lung cancer. Liquid biopsy tests involve analyzing a patient’s blood, urine, or other body fluids for the detection of biomarkers, including circulating tumor cells or tumor-derived DNA/RNA that have been shed into the bloodstream. Studies have shown that liquid biopsies can detect lung cancer metastases with high accuracy and sensitivity, even before they are visible on imaging scans. Such tests are valuable for early intervention and personalized treatment, aiming to improve patient outcomes. Liquid biopsies are also minimally invasive compared to traditional tissue biopsies, which require the removal of a sample of the tumor for further analysis. This makes liquid biopsies a more convenient and less risky option for patients, particularly those who are not good candidates for invasive procedures due to other medical conditions. While liquid biopsies for lung cancer metastases and relapse are still being developed and validated, they hold great promise for improving the detection and treatment of this deadly disease. Herein, we summarize available and novel approaches to liquid biopsy tests for lung cancer metastases and recurrence detection and describe their applications in clinical practice.

26 October 2023 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
Iael Weissberg MinutentagIael Weissberg Minutentag
Iael Weissberg Minutentag
ASAna Laura Seneda
Ana Laura Seneda
MBMateus Barros-Filho
Mateus Barros-Filho
MCMárcio de Carvalho
Márcio de Carvalho
VSVanessa G. P. Souza
Vanessa G. P. Souza
SDSandra Aparecida Drigo
Sandra Aparecida Drigo
Deregulated miRNAs are associated with colorectal cancer (CRC), with alterations depending on the tumor location. Novel tissue-specific miRNAs have been identified in different tumors and are associated with cancer. We used miRMaster to identify novel miRNAs in CRC from the TCGA and GEO data (discovery and validation groups). We used TCGA data from five tissues to analyze miRNA tissue specificity. miRDB was used to predict miRNA targets, and the UCSC Xena Browser was used to evaluate target expression. After successive analyses, we identified 15 novel miRNAs with the same expression patterns in CRC in both the discovery and validation groups. Four molecules (nov-miR-13844-5p, nov-miR-7154-5p, nov-miR-5035-3p, and nov-miR-590-5p) were differentially expressed in proximal and distal CRC. The nov-miR-3345-5p and nov-miR-13172-3p, which are upregulated in tumors, are only expressed in colorectal tissues. These molecules have been linked to a worse prognosis in right-sided colon and rectal carcinomas. An analysis revealed an association between eight novel miRNAs and 81 targets, mostly cancer-related genes, with varying expression based on tumor location. These findings provide new miRNAs with potential biological relevance, molecular biomarkers, and therapeutic targets for CRC treatment.

Verified
Journal Article
Open access
PDF file
LRLenize da Silva Rodrigues
Lenize da Silva Rodrigues
Tainara Francini FelixTainara Francini Felix
Tainara Francini Felix
Iael Weissberg MinutentagIael Weissberg Minutentag
Iael Weissberg Minutentag
PRPatricia Reis
Patricia Reis
MBMatheus Bertanha
Matheus Bertanha
MicroRNAs (miRNAs) are non-coding RNAs involved in the regulation of gene expression associated with cell differentiation, proliferation, adhesion, and important biological functions such as inflammation. miRNAs play roles associated with the pathogenesis of chronic degenerative disorders including cardiovascular diseases. Understanding the influence of miRNAs and their target genes can effectively streamline the identification of key biologically active pathways that are important in the development of vascular grafts through the tissue engineering of blood vessels. To determine miRNA expression levels and identify miRNA target genes and pathways with biological roles in scaffolds that have been repopulated with adipose-derived stem cells (ASCs) generated through tissue engineering for the construction of blood vessels. miRNA quantification assays were performed in triplicate to determine miRNA expression in a total of 20 samples: five controls (natural inferior vena cava), five scaffolds recellularized with ASCs and differentiated into the endothelium (luminal layer), five samples of complete scaffolds seeded with ASCs differentiated into the endothelium (luminal layer) and smooth muscle (extraluminal layer), and five samples of ASC without cell differentiation. Several differentially expressed miRNAs were identified and predicted to modulate target genes with roles in key pathways associated with angiogenesis, vascular system control, and endothelial and smooth muscle regulation, including migration, proliferation, and growth. These findings underscore the involvement of these pathways in the regulatory mechanisms that are essential for vascular scaffold production through tissue engineering. Our research contributes to the knowledge of miRNA-regulated mechanisms, which may impact the design of vascular substitutes, and provide valuable insights for enhancing clinical practice. The molecular pathways regulated by miRNAs in tissue engineering of blood vessels (TEBV) allowed us to elucidate the main phenomena involved in cellular differentiation to constitute a blood vessel, with the main pathways being essential for angiogenesis, cellular differentiation, and differentiation into vascular smooth muscle.

1 March 2026 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
NCNara Aline Costa
Nara Aline Costa
APAmanda Gomes Pereira
Amanda Gomes Pereira
HRHellen Christina Neves Rodrigues
Hellen Christina Neves Rodrigues
LCLilian Cuppari
Lilian Cuppari
Tainara Francini FelixTainara Francini Felix
Tainara Francini Felix
MMMarcos Minicucci
Marcos Minicucci
Introduction: The investigation of circulating microRNAs (miRNAs) and inflammatory response associated with the different stages of chronic kidney disease (CKD) may reveal biomarkers of disease pathogenesis. Our goal was to identifying differences in the circulating miRNAs expression between peritoneal dialysis (PD) and non-dialytic (ND) patients and determine the regulatory miRNA-target gene networks and pathways potentially involved in disease pathogenesis. Methods: This was an exploratory cross-sectional study that included ND and PD patients with CKD stage 5 over 18 years of age. Inflammatory biomarkers and circulating miRNA expression profiles were evaluated. Results: The study included 20 patients (57.2 ± 11.8 years). Levels of high-sensitivity C-reactive protein [0.37 (0.07–1.40) vs. 3.90 (2.50–5.79), p = 0.038] and interleukin-6 [3.35 ± 3.08 vs. 6.82 ± 4.08, p = 0.046] were significantly lower in the ND group in comparison to the PD group, respectively. Nine miRNAs were significantly deregulated (fold change (FC) ≥ 2 and p ≤ 0.05) in the PD compared to the ND group. Computational analyses showed a large number of target genes commonly regulated by at least two of the identified miRNAs. Pathway enrichment analysis showed that G protein-coupled receptor (GPCR) signaling, insulin secretion/resistance, and energy metabolism were among significant pathways regulated by miRNA target genes. Conclusions: Patients on PD treatment showed deregulated circulating levels of the 9 identified miRNAs and higher serum inflammatory biomarkers, compared to ND patients. Genes regulated by miRNAs are mainly associated with GPCR signaling, insulin resistance, and energy metabolism, playing roles in fibrosis and inflammatory-associated functions.

1 March 2026 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
NCNara Aline Costa
Nara Aline Costa
APAmanda Gomes Pereira
Amanda Gomes Pereira
HRHellen Christina Neves Rodrigues
Hellen Christina Neves Rodrigues
LCLilian Cuppari
Lilian Cuppari
Tainara Francini FelixTainara Francini Felix
Tainara Francini Felix
MMMarcos Minicucci
Marcos Minicucci
Resumo Introdução: A investigação de microRNAs (miRNAs) circulantes e da resposta inflamatória associada aos diferentes estágios da DRC pode revelar biomarcadores da patogênese da doença. Nosso objetivo foi identificar diferenças na expressão de miRNAs circulantes entre pacientes em diálise peritoneal (DP) e não dialíticos (ND), determinando redes regulatórias da interação miRNA-gene-alvo e vias potencialmente envolvidas na patogênese da doença. Métodos: Estudo transversal exploratório incluindo pacientes ND e em DP com DRC estágio 5 e idade superior a 18 anos. Avaliaram-se biomarcadores inflamatórios e perfis de expressão de miRNA circulantes. Resultados: Foram incluídos 20 pacientes (57,2 ± 11,8 anos). Níveis de proteína C-reativa de alta sensibilidade [0,37 (0,07–1,40) vs. 3,90 (2,50–5,79); p = 0,038] e interleucina-6 [3,35 ± 3,08 vs. 6,82 ± 4,08; p = 0,046] foram significativamente menores no grupo ND comparados ao grupo DP, respectivamente. Nove miRNAs apresentaram desregulação significativa (fold change (FC) ≥ 2 e p ≤ 0,05) no grupo DP comparado ao grupo ND. Análises computacionais revelaram grande número de genes-alvo comumente regulados por pelo menos dois dos miRNAs identificados. A análise de enriquecimento de vias demonstrou que sinalização por receptor acoplado à proteína G (GPCR), secreção/resistência à insulina e metabolismo energético estiveram entre as vias significativas reguladas pelos genes-alvo do miRNA. Conclusões: Pacientes em tratamento com DP apresentaram níveis circulantes desregulados dos 9 miRNAs identificados e biomarcadores inflamatórios séricos mais elevados, comparados aos pacientes ND. Genes regulados pelos miRNAs associam-se principalmente à sinalização por GPCR, resistência à insulina e metabolismo energético, desempenhando papéis na fibrose e funções associadas à inflamação.